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Some children with autism spectrum disorders (ASD; 15% to 30% of patients) show a significant and persistent
regression in speech and social function during early childhood. There are no established treatments for the
regressive symptoms. However, there are some known causes of this type of regression, such as Rett syndrome and
Landau-Kleffner syndrome (LKS). In LKS, steroids have been used as a treatment. Some evidence suggests an
autoimmune contribution to the pathophysiology of autism (Chez MG, Guido-Estrada N: Immune therapy in autism:
historical experience and future directions with immunomodulatory therapy. Neurotherapeutics 2010, 7:293–301,
Wasilewska J, Kaczmarski M, Stasiak-Barmuta A, Tobolczyk J, Kowalewska E: Low serum IgA and increased expression
of CD23 on B lymphocytes in peripheral blood in children with regressive autism aged 3-6 years old. Arch Med Sci
2012, 8:324–331, Stefanatos G: Changing perspectives on Landau-Kleffner syndrome. Clin Neuropsychol 2011,
25:963–988), raising the possibility that steroids might be a useful therapy for regression in ASD. A retrospective study
published in BMC Neurology by Duffy et al. (Duffy, et al: Corticosteroid therapy in regressive autism: A retrospective study
of effects on the Frequency Modulated Auditory Evoked Response (FMAER), language, and behavior. BMC Neurol 2014,
14:70) reviewed 20 steroid treated R-ASD (STAR) patients and 24 ASD control patients not treated with steroids (NSA).
Improvements in clinical function and in a neurophysiological biomarker were seen in the steroid-treated children
pre- to post-prednisolone treatment. This research provides a rationale for a randomized trial with steroid therapy to
determine the longer term benefits and complications of steroids in this population.
Please see related article http://www.biomedcentral.com/1471-2377/14/70/abstract.
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Regression is a highly distinctive feature in some patients
with autism characterized by sustained loss of normally
developing language and social skills around the age of
15 to 30 months [1]. Regressive features in patients with
autism spectrum disorders (ASD) are estimated to occur
in as many as 32% of cases, with a mean age of presentation
of 1.8 years [2]. It remains to be determined whether this is
a biologically distinct form of autism, and currently there
are few treatment options to stop or reverse the regression
process. An immunologic basis for the pathogenesis of
some forms of autism has been hypothesized [3,4], and im-
mune system dysfunction, especially involving B-cell activa-
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2014of regression in ASD [5]. In this case, steroids could have a
role in arresting progression of such symptoms. They have
been successfully used in related epileptic syndromes such
as Landau-Kleffner syndrome [LKS] which is associated
with regression of speech and acquired epileptiform aphasia
[6]. Knowledge of benefits from steroid use in treating
regressive autism is limited to small studies. In one case
study, a previously developmentally normal child who had
autistic regression was treated with low dose steroids with
improved speech and developmental milestones in the set-
ting of an autoimmune spectrum of lymphoproliferation
and autoimmune hemolytic anemia [7].
In a retrospective case-control study by Duffy et al. [8],
the authors summarize their single-center experience with
steroid treatment using an innovative EEG/ERP biomarker
strategy monitoring the frequency modulated auditory
evoked response (FMAER).entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly cited.
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The rationale and procedures for evaluating the FMAER
have previously been described [9]. In brief, evoked re-
sponses in the auditory cortex to rapid auditory stimulus
frequency modulation can be used to monitor neuro-
physiological processes that are important for phoneme
detection and language processing. It is a promising, ob-
jective diagnostic tool for detecting sensory processing
abnormalities in the auditory cortex of functional signifi-
cance, and a potential biomarker for identifying sub-
groups of patients for novel treatments and for tracking
effects of novel therapies. In this retrospective study, the
investigators selected 20 target group children (STAR)
with a documented regressive course of autism who had
received steroid therapy (prednisolone) and 24 untreated
comparison subjects from an existing clinical database [8].
Change in clinical status and FMAER after treatment were
assessed and compared with change in controls (NA). The
STAR group showed a significant clinical improvement
after steroids in receptive and expressive language skills
and behavioral manifestations of autism. Improvement in
the FMAER was also seen. Almost all patients in the STAR
group had steroid related side effects, the majority of which
were mild and reversible.
Potential for steroid therapy?
This study offers promising new data regarding the po-
tential of steroid therapy in regressive autism. While
supporting the rationale for a randomized multi-site
trial to establish efficacy of the therapy, it is important
to recognize that this is a retrospective study involving
a small group of children [8]. Factors impacting deci-
sion to treat in the clinic might have influenced study
findings. There are a significant number of side effects
associated with steroids that need to be considered in
evaluating risks as well as benefits of the treatment.
Treated patients may need close monitoring, including
frequent checks of blood pressure, blood glucose, weight
gain and potential behavioral effects including mood
change and psychosis. A longer trial with consistent
follow-up would better establish beneficial changes in
language and behavior. Since steroids have been suc-
cessfully used in multiple neurologic disorders including
autoimmune neurologic disorders, epilepsy, muscular
dystrophies and encephalitis, neurologists are familiar
with their use which could facilitate their use for regres-
sive autism if efficacy can be established.
Conclusions
This study showing improved function over time in
steroid-treated children with regressive autism provides
a rationale for a randomized trial of steroid treatment in
this population, for which no current treatments are
available. Corticosteroids have numerous adverse effects,some of which can lead to potentially serious complica-
tions, so a detailed cost-benefit analysis of this treatment
in a randomized trial is needed to establish that benefits
outweigh risks in this population. This study also provides
preliminary support for the use of FMAER as an urgently
needed and objective biomarker for evaluating treatment
effects on brain function for children with autism, at least
for those with regression of language skills.
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